Evidence map›Paper›PMID 27447724›Full record

ArticlePloS one2016

Development of Novel Erythromycin Derivatives with Inhibitory Activity against Proliferation of Tumor Cells.

Lan Wu, Kai Bao, Rui Song, Defa Wang, Lei Zhang, Weiyun Wang, Weige Zhang, Wen Bin

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lan WuDepartment of Geratology, The First Affiliated Hospital of Chinese Medical University, Shenyang, China.
Kai BaoState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Rui SongSchool of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
Defa WangKey Laboratory of Structure-Based Drug Design and Discovery Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China.
Lei ZhangDepartment of Geratology, The First Affiliated Hospital of Chinese Medical University, Shenyang, China.
Weiyun WangSchool of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
Weige ZhangKey Laboratory of Structure-Based Drug Design and Discovery Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China.
Wen BinSchool of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In our continuing structure-activity relationship study of a new class of erythromycin A (EM-A) derivatives with antiproliferative activity, a new series of de(N-methyl) EM-A dimers jointed by a four-atom linker, -CH2CH = CHCH2-, were prepared and their antiproliferative activity against three human tumor cell lines was evaluated by MTT assay. The most active EM-A dimer, compound 1b, that carrying C6 methoxyl groups was further investigated and showed potent antiproliferative activity in six other human tumor cell lines. Flow cytometry analysis of 1b treated HeLa and MCF-7 cells indicated that the four-atom EM-A dimers induced the SubG1 phase cell cycle arrest and cell apoptosis, in time- and dose-dependent manners. Further experiments including morphologic observation, DNA agarose gel electrophoresis, mitochondrial potential alternation and western blot analysis revealed that the antiproliferative mechanism may involve the induction of apoptosis in activating the mitochondrial pathway, and regulation of apoptotic proteins.

Indexed as

Drug DiscoveryAntineoplastic AgentsApoptosisApoptosis Regulatory ProteinsBiomarkersCell Cycle CheckpointsCell Line, TumorCell ProliferationDNA FragmentationErythromycinHumansMembrane Potential, MitochondrialMolecular StructureAntineoplastic AgentsApoptosis Regulatory ProteinsBiomarkersErythromycin

Identifiers

PMID27447724
PMCPMC4957748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.